ASX-listed Dimerix has landed one of the biggest licensing deals by an Australian biotechnology company after US pharmaceutical group Amicus Therapeutics agreed to $940 million in payments for future sales of its kidney disease drug.
Shares in Melbourne-based Dimerix were trading 50 per cent higher on news of the breakthrough on Thursday afternoon, valuing the company at $400 million. The biotech group counts former Fortescue Metals and WorleyParsons executive Peter Meurs as its biggest shareholder, with a 13.5 per cent stake.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。